USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ITI HEALTH, INC.
Address:
1076 AUTUMN HILL CT
CROZET, VA 22932-3140
Phone:
N/A
URL:
N/A
EIN:
127395359
DUNS:
964923747
Number of Employees:
N/A
Woman-Owned?:
Yes
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $850,670.00 3

Award List:

Developing a plectin-1 targeted imaging agent for the detection of pancreatic can

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$299,999.00
Agency:
HHS
Principal Investigator:
Greg B. Fralish – 434-298-4844
Abstract:
DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is an intractable clinical problem, typically presenting with metastasis at the time of diagnosis and exhibiting profound resistance to existing therapies. Currently, the standarddiagnostic course includes CT or MRI scans… More

TAS::75 0849::TAS SBIR TOPIC 307 PHASE I NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOLKIT FOR CANCER DIAGNOSIS, STAGING, AND TREATMENT

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$249,330.00
Agency:
HHS
Principal Investigator:
Greg Fralish – 434-298-4844
Abstract:
Phase I - Topic 307 The long term objective of this work is to transform the clinical practice of diagnosing and treating pancreatic cancer through the development of a targeted imaging reagent. The 5-year survival rate for patients diagnosed with pancreatic cancer is less than 5%. Those with… More

Development of a plectin-1 targeted payload delivery system for treating pancreat

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$301,341.00
Agency:
HHS
Principal Investigator:
Greg B. Fralish – 434-298-4844
Abstract:
DESCRIPTION (provided by applicant): While only the 31st most common cause of cancer, pancreatic cancer is the fourth most common cause of cancer-related death in the US. Patients typically present with advanced disease that is notoriously refractory to chemotherapy. Indeed, the 5 year survival rate… More